Title |
Considerations in the development of circulating tumor cell technology for clinical use
|
---|---|
Published in |
Journal of Translational Medicine, July 2012
|
DOI | 10.1186/1479-5876-10-138 |
Pubmed ID | |
Authors |
David R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, Carolyn Compton, Massimo Cristofanilli, Albert Deisseroth, Daniel F Hayes, Gordon Kapke, Prasanna Kumar, Jerry SH Lee, Minetta C Liu, Robert McCormack, Stanislaw Mikulski, Larry Nagahara, Klaus Pantel, Sonia Pearson-White, Elizabeth A Punnoose, Lori T Roadcap, Andrew E Schade, Howard I Scher, Caroline C Sigman, Gary J Kelloff |
Abstract |
This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 57% |
Netherlands | 1 | 14% |
Unknown | 2 | 29% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 86% |
Scientists | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 2% |
France | 2 | <1% |
India | 2 | <1% |
United Kingdom | 1 | <1% |
Germany | 1 | <1% |
Spain | 1 | <1% |
China | 1 | <1% |
Unknown | 300 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 69 | 22% |
Researcher | 60 | 19% |
Student > Master | 34 | 11% |
Other | 18 | 6% |
Student > Doctoral Student | 15 | 5% |
Other | 59 | 19% |
Unknown | 58 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 66 | 21% |
Medicine and Dentistry | 53 | 17% |
Engineering | 46 | 15% |
Biochemistry, Genetics and Molecular Biology | 38 | 12% |
Chemistry | 14 | 4% |
Other | 27 | 9% |
Unknown | 69 | 22% |